onc brain

The longer read

The interesting choice here is the refusal to choose. Faced with a resected primary and no GTV, a contouring guideline has two obvious surrogates available, the re-created pre-operative tumour volume and the operative bed (surgical defect or reconstruction flap), and the path of least resistance would have been to nominate one and write the rules around it. This document contours both independently, gives them different margins, and takes the union. The justification sits in the example cases rather than in any outcome data: Fig 3.1 and 3.2 show a buccal mucosa case where the re-created pre-op GTV extends superiorly past the surgical defect toward the infratemporal fossa, and the authors state plainly that relying on the defect alone would have produced a geographical miss there. Fig 6 runs the argument the other way, an ill-defined buccal fat pad reconstruction that can only be outlined with significant uncertainty, where the pre-op GTV does the load-bearing work. Two surrogates that fail in different directions, so use both.

The margins themselves are inherited rather than derived. The 10 mm around GTV-P pre-op is explicitly the same 5+5 mm geometric expansion the 2018 definitive-setting consensus advocated, and the supporting biology is a surgical pathology observation that microscopic infiltration is seen within 5 mm of the GTV-P edge in over 95 % of resected OCSCC. The 5 mm added to the defect or flap is asserted as sufficient short of R2 resection. Neither number comes from post-operative recurrence mapping, which is the study that does not exist and would be the real evidentiary basis. A reader should hold these as reasonable geometric conventions with a plausible pathological rationale, not as validated thresholds, and note that the field has been moving in the opposite direction in the definitive setting, where the Dutch series cited here reduced the high-risk margin from 10 mm to 6 mm and reported lower salivary and constrictor dose with lower toxicity. That tension is unresolved in the post-op setting and the guideline does not pretend otherwise.

The nodal half is where the practice change is sharpest, because the recommendation is margin-by-biology rather than level-by-atlas. Recreating GTV-N pre-op and expanding 5 mm without pENE, 10 mm with, is defended in Fig 11.2 and 12.2 by showing standard level-based contours failing: a level II node abutting digastric, and a level Ib node sitting near the caudal border of the level, where atlas boundaries would leave inadequate soft tissue margin below the resected node. This is a genuine argument that nodal level atlases, designed for elective coverage of undissected necks, are the wrong tool for a specific resected node with a disrupted capsule. It also has a dosimetric payoff the guideline names: a targeted CTV-N high-risk around the surrogate can be smaller than escalating an entire level to 64-66 Gy.

What should temper confidence is the co-registration dependency. The whole surrogate method presumes a pre-operative MRI or CT that can be rigidly matched to the planning scan; where it cannot, the stated fallback is to contour the entire involved level, and with pENE to escalate that whole level to high dose. So the guideline's benefit accrues disproportionately to centres with good pre-op imaging and fusion workflow, and the failure mode is systematically larger volumes for everyone else. Similarly the dose to dissected but uninvolved levels rests on a 1993 MD Anderson observation about perturbed tissue, never tested prospectively, and is left at clinician discretion across EQD2 50 to 60 Gy, which is an honest admission that a common daily decision has no evidence behind it. The authors are explicit that prospective audit is what would establish this as standard of care. Read it as a well-reasoned standardisation of a previously unstandardised task, valuable most immediately for trial QA and multi-institutional audit, and as a testable hypothesis about where recurrences actually occur.